Evidence map›Paper›PMID 33986988›Full record

ArticlePeerJ2021

Yi-Wei Kuo, Shih-Hung Hsieh, Jui-Fen Chen, Cheng-Ruei Liu, Ching-Wei Chen, Yu-Fen Huang, Hsieh-Hsun Ho

Open access · goldAbstract read
In one paragraph

Article in PeerJ, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 89 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Biological Characteristics of a ProbioticFoods (Basel, Switzerland) · 2026
    Article
  6. Review
  7. Synergistic effect of a naturally derivedBioscience of microbiota, food and health · 2026
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Probiotic potential ofFrontiers in microbiology · 2025
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yi-Wei KuoResearch and Development Department, Glac Biotech Co., Ltd., Tainan, Taiwan.
Shih-Hung HsiehResearch and Development Department, Glac Biotech Co., Ltd., Tainan, Taiwan.
Jui-Fen ChenResearch and Development Department, Glac Biotech Co., Ltd., Tainan, Taiwan.
Cheng-Ruei LiuResearch and Development Department, Glac Biotech Co., Ltd., Tainan, Taiwan.
Ching-Wei ChenResearch and Development Department, Glac Biotech Co., Ltd., Tainan, Taiwan.
Yu-Fen HuangResearch and Development Department, Glac Biotech Co., Ltd., Tainan, Taiwan.
Hsieh-Hsun HoResearch and Development Department, Glac Biotech Co., Ltd., Tainan, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUric acid (UA) is the end product of purine metabolism in the liver and is excreted by the kidneys. When purine metabolism is impaired, the serum UA level will be elevated (hyperuricemia) and eventually lead to gout. During evolution, humans and some primates have lost the gene encoding uricase, which is vital in UA metabolism. With the advances of human society, the prevalence of hyperuricemia has dramatically increased because of the refined food culture. Hyperuricemia can be controlled by drugs, such as allopurinol and probenecid. However, these drugs have no preventive effect and are associated with unpleasant side effects. An increasing number of probiotic strains, which are able to regulate host metabolism and prevent chronic diseases without harmful side effects, have been characterized. The identification of probiotic strains, which are able to exert beneficial effects on UA metabolism, will provide an alternative healthcare strategy for patients with hyperuricemia, especially for those who are allergic to anti-hyperuricemia drugs.

methodsTo elicit hyperuricemia, rats in the symptom control group (HP) were injected with potassium oxonate and fed a high-purine diet. Rats in the probiotic groups received the high-purine diet, oxonate injection, and supplements of probiotic strains TSR332, TSF331, or La322. Rats in the blank control group (C) received a standard diet (AIN-93G) and oxonate injection.

resultsPurine-utilizing strains of probiotics were screened using high-pressure liquid chromatography (HPLC) in vitro, and the lowering effect on serum UA levels was analyzed in hyperuricemia rats in vivo. We found that

Indexed as

GoutHyperuricemiaLactobacillusProbioticsPurine metabolism

Identifiers

PMID33986988
PMCPMC8101448
OpenAlexW3158015461

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.